- Home
- CTRA vs RPRX Comparison
CTRA vs RPRX Comparison
Compare CTRA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRA
- RPRX
- Stock Information
- Founded
- CTRA 1989
- RPRX 1996
- Country
- CTRA United States
- RPRX United States
- Employees
- CTRA N/A
- RPRX N/A
- Industry
- CTRA Oil & Gas Production
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CTRA Energy
- RPRX Health Care
- Exchange
- CTRA Nasdaq
- RPRX Nasdaq
- Market Cap
- CTRA 18.0B
- RPRX 16.2B
- IPO Year
- CTRA 1990
- RPRX 2020
- Fundamental
- Price
- CTRA $26.60
- RPRX $38.51
- Analyst Decision
- CTRA Buy
- RPRX Strong Buy
- Analyst Count
- CTRA 17
- RPRX 3
- Target Price
- CTRA $32.65
- RPRX $46.00
- AVG Volume (30 Days)
- CTRA 10.4M
- RPRX 3.4M
- Earning Date
- CTRA 11-03-2025
- RPRX 11-05-2025
- Dividend Yield
- CTRA 3.31%
- RPRX 2.28%
- EPS Growth
- CTRA 31.20
- RPRX N/A
- EPS
- CTRA 2.17
- RPRX 1.75
- Revenue
- CTRA $6,666,000,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- CTRA $47.08
- RPRX $36.16
- Revenue Next Year
- CTRA $7.39
- RPRX $2.04
- P/E Ratio
- CTRA $12.27
- RPRX $22.01
- Revenue Growth
- CTRA 25.92
- RPRX 3.70
- 52 Week Low
- CTRA $22.33
- RPRX $24.05
- 52 Week High
- CTRA $29.95
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- CTRA 76.25
- RPRX 56.61
- Support Level
- CTRA $23.19
- RPRX $36.03
- Resistance Level
- CTRA $23.91
- RPRX $41.24
- Average True Range (ATR)
- CTRA 0.57
- RPRX 1.17
- MACD
- CTRA 0.37
- RPRX 0.28
- Stochastic Oscillator
- CTRA 92.62
- RPRX 48.17
About CTRA Coterra Energy Inc.
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.